Search research articles
Contact Us
Filters
Showing results (81-90 of 94) with videos related to
Page
of 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2015
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models
Alwin G Schuller, Evan R Barry, Rhys D O Jones, et al.
Journal for Immunotherapy of Cancer
|
August 8, 2023
Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma
Vincenzo Graziano, Andreas Dannhorn, Heather Hulme, et al.
Journal for Immunotherapy of Cancer
|
May 16, 2020
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade
Rui Yang, Samah Elsaadi, Kristine Misund, et al.
Journal of Medicinal Chemistry
|
November 22, 2024
Discovery of (2<i>R</i>,4<i>R</i>)-4-((<i>S</i>)-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat Cancer
Scott N Mlynarski, Brian M Aquila, Susan Cantin, et al.
Journal for Immunotherapy of Cancer
|
July 31, 2020
Small molecule AZD4635 inhibitor of A<sub>2A</sub>R signaling rescues immune cell function including CD103<sup>+</sup> dendritic cells enhancing anti-tumor immunity
Alexandra Borodovsky, Christine M Barbon, Yanjun Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 18, 2010
Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies
Seth A Ettenberg, Olga Charlat, Michael P Daley, et al.
Molecular Cancer Therapeutics
|
March 13, 2023
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners
Aatman S Doshi, Susan Cantin, Marylens Hernandez, et al.
Communications Biology
|
January 26, 2021
Design and optimisation of dendrimer-conjugated Bcl-2/x<sub>L</sub> inhibitor, AZD0466, with improved therapeutic index for cancer therapy
Claire M Patterson, Srividya B Balachander, Iain Grant, et al.
Plos One
|
October 8, 2014
MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis
Robert N Booher, Harold Hatch, Brian M Dolinski, et al.
RSC Medicinal Chemistry
|
June 16, 2025
Synthetic chemistry enabling the discovery and development of a series of pyrazoles as HPK1 inhibitors
Anthony J Metrano, Lucas A Morrill, Gayathri Bommakanti, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 94) with videos related to
Sort By:
Page
of 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2015
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models
Alwin G Schuller, Evan R Barry, Rhys D O Jones, et al.
Journal for Immunotherapy of Cancer
|
August 8, 2023
Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma
Vincenzo Graziano, Andreas Dannhorn, Heather Hulme, et al.
Journal for Immunotherapy of Cancer
|
May 16, 2020
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade
Rui Yang, Samah Elsaadi, Kristine Misund, et al.
Journal of Medicinal Chemistry
|
November 22, 2024
Discovery of (2<i>R</i>,4<i>R</i>)-4-((<i>S</i>)-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat Cancer
Scott N Mlynarski, Brian M Aquila, Susan Cantin, et al.
Journal for Immunotherapy of Cancer
|
July 31, 2020
Small molecule AZD4635 inhibitor of A<sub>2A</sub>R signaling rescues immune cell function including CD103<sup>+</sup> dendritic cells enhancing anti-tumor immunity
Alexandra Borodovsky, Christine M Barbon, Yanjun Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 18, 2010
Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies
Seth A Ettenberg, Olga Charlat, Michael P Daley, et al.
Molecular Cancer Therapeutics
|
March 13, 2023
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners
Aatman S Doshi, Susan Cantin, Marylens Hernandez, et al.
Communications Biology
|
January 26, 2021
Design and optimisation of dendrimer-conjugated Bcl-2/x<sub>L</sub> inhibitor, AZD0466, with improved therapeutic index for cancer therapy
Claire M Patterson, Srividya B Balachander, Iain Grant, et al.
Plos One
|
October 8, 2014
MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis
Robert N Booher, Harold Hatch, Brian M Dolinski, et al.
RSC Medicinal Chemistry
|
June 16, 2025
Synthetic chemistry enabling the discovery and development of a series of pyrazoles as HPK1 inhibitors
Anthony J Metrano, Lucas A Morrill, Gayathri Bommakanti, et al.
Page
of 10